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doi:10.1016/j.jtcvs.2007.07.066Objectives: In the past few years there has been increasing evidence that the respira-
tory function of patients with diabetes is impaired in the course of their disease. The
objective of this article was to investigate whether patients with diabetes are particu-
larly at risk of pulmonary complications during the perioperative stage of coronary
bypass surgery.
Methods: The data of 8555 patients who had undergone coronary bypass operations in
the years between 1996 and 2004 were analyzed. Depending on their diagnosis on ad-
mission and their fasting plasma glucose levels, these patients were classified as hav-
ing ‘‘no diabetes’’ (fasting plasma glucose level , 126 mg/dL), ‘‘undiagnosed
diabetes’’ (glucose level $ 126 mg/dL), ‘‘oral therapy diabetes,’’ or ‘‘insulin-treated
diabetes.’’ The 3 diabetic groups were compared with the nondiabetic group in terms
of the preoperative and postoperative characteristics.
Results: The reintubation rate among patients with undiagnosed diabetes (4.6%) and
among those with insulin-treated diabetes (4.5%) was significantly higher than that of
nondiabetic patients (1.8%; P , .01). The proportion of patients who required respi-
ration for periods longer than 1 day was also significantly higher among patients with
undiagnosed diabetes (9.9%) and those with insulin-treated diabetes (8.6%) than
among the nondiabetic patients (4.8%; P, .01). The regression models show that un-
identified diabetes and insulin-treated diabetes constitute independent risk factors for
perioperative pulmonary complications.
Conclusions: Patients with undiagnosed and insulin-treated diabetes have a higher
risk of having pulmonary complications in the perioperative course of coronary by-
pass operations than do nondiabetic patients. These results may be explained if one
considers the lung as another target organ of the diabetic disease.
E
arlier investigations involving lung function in individuals with type 1 diabetes
suggested that the lung may also be a target organ of the diabetic disease.
Schuyler and associates1 showed, for instance, that lung elastic recoil was re-
duced in patients with type 1 diabetes. Sandler and colleagues2 reported reduced lung
elasticity, a lower carbon monoxide transfer capacity, and a smaller pulmonary cap-
illary blood volume. In the following years, the concept of the lung as a target organ of
diabetic micro-angiopathy gained further attention. Sandler3 concluded that the lung
ought to be considered as a potential target organ of diabetes mellitus, but they also
found that the pathophysiologic changes observed were relatively minor and that,
as a result, no clear clinical implications of these findings could be determined. Later
investigations into the lung transfer capacity for carbon monoxide4 and postmortem
histopathologic studies5 provided further evidence that the lung is a target organ of
micro-angiopathy in both type 1 and type 2 diabetes. It was shown, however, that
the simple pulmonary function tests underrated the prevalence and the extent of
lung dysfunction in patients with diabetes.
Cardiac surgeons have been familiar for quite some time with what is known as
‘‘pulmonary injury,’’ particularly during extracorporeal circulation,6,7 with the causesThe Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1047
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FEV1 5 forced expiratory volume in 1 second
FPG 5 fasting plasma glucose
FVC 5 forced vital capacity
ICU 5 intensive care unit
seen as (1) contact of the blood constituents with the artificial
surface of the tube system, (2) ischemia/reperfusion damage,
(3) endotoxemia, and (4) operative trauma. Proven effects
include the activation of the complementary system, the acti-
vation of neutrophils, the adhesion of neutrophils to the endo-
thelium of lung vessels, and endothelial damage caused by
proteases. Lung damage after cardiopulmonary bypass also
causes higher lung permeability, higher pulmonary vascular
resistance, and changes in lung surfactants. Subsequent
effects include pulmonary edema, alveolar protein accumula-
tion, and the increased sequestration of inflammatory cells,7
which, in turn, impairs pulmonary function.
Against this background, the question arises whether pa-
tients with diabetes are particularly at risk of pulmonary com-
plications in the perioperative course of coronary bypass
operations.
Materials and Methods
The study included 8555 patients who had undergone elective cor-
onary bypass operations at the Heart Institute Lahr/Baden in the
period between January 1996 and December 2004. Patients who
underwent emergency interventions, combined procedures, and
‘‘redo’’ operations were excluded from the study. Patient care,
both at the operative and the postoperative stages, followed the
standardized guidelines of our hospital. Only membrane oxygena-
tors were used in the extracorporeal circulation, with blood cardi-
oplegia used as the cardioplegic solution. To avoid thermal damage
of the phrenic nerve, we used no additional external topical cooling
of the myocardium. All patients underwent hourly control of
plasma glucose during the operation and the first 36 hours postop-
eratively, followed by 6 hourly plasma glucose readings until hos-
pital discharge. Therapeutic aim was to achieve near-normal
glycemia. Continuous intravenous insulin infusions during the
operation and the immediate postoperative phase, as well as subcu-
taneous insulin application added by oral antidiabetic therapy in
the later phase, were used to achieve this goal. Blood glucose con-
trol with continuous intravenous insulin infusion was initiated at
a threshold level of 150 mg/dL. Insulin was started in the operating
room before sternotomy and after induction of anesthesia. The
perioperative and postoperative blood glucose target was 100 to
150 mg/dL, and insulin dose was adapted according to the Portland
protocol.8
For each patient included in the present study, 32 preoperative
characteristics and 8 postoperative progress values were used
from the consolidated database of our Data Mart system.9 The
data were based on information from anesthesiologic and cardiac
surgical quality assurance figures and clinical chemistry laboratory
results.1048 The Journal of Thoracic and Cardiovascular Surgery c MDefinitions
The following definitions, essentially applied in analogy with the
EuroSCORE,10 were used for the risk factors investigated:
 Peripheral vascular disease: claudication, previous or
planned intervention involving the arteries of the limbs
 Carotid disease: carotid occlusion or greater than 50% steno-
sis, previous or planned intervention on the carotids
 Neurologic dysfunction: severely affecting ambulation or
day-to-day functioning
 Chronic obstructive pulmonary disease: long-term use of
bronchodilators or steroids for lung disease
 Pulmonary hypertension: systolic pulmonary artery pressure
greater than 60 mm Hg
 Recent myocardial infarction: infarction within 90 days
 Unstable angina: rest angina requiring intravenous nitrates
until arrival in the anesthetic room; patientswhowere not fully
without symptoms under intravenous nitrate medication were
declared as ‘‘emergency cases’’ and excluded from the study
 Stroke: a new focal neurologic deficit or coma lasting more
than 24 hours, associated with computed tomographic dem-
onstration or recent ischemic cerebral lesion
 Cerebral dysfunction: in comparison with the preoperative
status, abnormalities in behavior and temporal and spatial dis-
orientation that are also clinically conspicuous without spe-
cific psychiatric examinations.
Diabetes was diagnosed by the current recommendations of the
American Diabetes Association11: The determination of the diabetes
status in epidemiologic studies is based on the measurement of the
fasting plasma glucose level (FPG $ 126 mg/dL [7.0 mmol/L]).
Patients admitted with a previous diagnosis of ‘‘diabetes mellitus’’
were classified either as having ‘‘oral therapy diabetes’’ or ‘‘insu-
lin-treated diabetes’’ in line with their previous therapies. The
remaining patients were classified in accordance with their FPG
level as having either ‘‘undiagnosed diabetes’’ (FPG $ 126 mg/
dL) or ‘‘no diabetes’’ (FPG, 126 mg/dL). These groups of patients
were compared in terms of their preoperative characteristics and risk
factors and the data of their postoperative progress.
Statistical Analysis
Univariate comparisons among the 4 patient groups investigated (no
diabetes, undiagnosed diabetes, oral therapy diabetes, and insulin-
treated diabetes) were performed by the c2 test for categorical vari-
ables and the Mann–Whitney test for continuous variables (SPSS
12.0; SPSS, Inc, Chicago, Ill). Stepwise logistic regression was
used to determine the predictors of the hospital outcomes of interest
by minimizing the so-called Akaike Information Criterion.
All baseline attributes and three additional dichotomous indica-
tor variables encoding the diabetes status were initially used in the
regression tasks. To obtain a nondiabetic reference group, we
defined the three indicator variables as follows: (1) undiagnosed
diabetes mellitus5 1 for patients with undiagnosed diabetes, 0 oth-
erwise; (2) oral therapy diabetes mellitus5 1 for patients with orally
treated diabetes, 0 otherwise; and (3) insulin-treated diabetes melli-
tus 5 1 for insulin-treated diabetes, 0 otherwise. In cases in which
only one or two indicator variables were significant in the final
model, the remaining one or two variables were forced into the
model. Model discrimination was evaluated by the area under the
receiver operating characteristic curve.ay 2008
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The distribution of the patients over the different patient
groups involved in the study and the initial parameters fully
included in the regression analysis are shown in Table 1. Hos-
pital outcome is shown in Table 2.
Patients with undiagnosed diabetes are significantly more
often in need of resuscitation than the other patient groups.
Postoperative renal failure requiring dialysis occurs signifi-
cantly more often among undiagnosed and insulin-treated
diabetic patients than in nondiabetic patients with coronaryThe Journal of Thoradisease. Perioperative strokes occur more frequently among
insulin-treated diabetic patients than in nondiabetic patients.
Also, diabetic patients more frequently experience conspicu-
ous mental disturbance in the postoperative period. Patients
with undiagnosed diabetes and insulin-treated diabetes are
significantly more often in need of reintubation in the postop-
erative period than nondiabetic patients (no diabetes 1.8% vs
undiagnosed diabetes 4.6% vs oral therapy diabetes 2.3% vs
insulin-treated diabetes 4.5%). The proportion of patients
who require ventilation for longer than 1 day is also highestA
CDTABLE 1. Baseline characteristics for the 4 patient groups
No diabetes
(n 5 5477)
Undiagnosed diabetes
(n 5 372)
Oral therapy diabetes
(n 5 1697)
Insulin-treated diabetes
(n 5 1009)
Demographic profile
Age (y) 65.05 6 9.58 66.20y 6 9.53 66.54* 6 8.30 66.56* 6 8.40
Female sex (%) 21.3 25.8 24.9* 39.5*
Body mass index (kg/m2) 27.44 6 3.89 27.85y 6 3.73 28.57* 6 4.11 28.87* 6 4.72
Medical history
Hypertension (%) 75.0 75.3 83.3* 86.6*
Peripheral vascular disease (%) 8.1 11.8y 10.8* 21.1*
Carotid disease (%) 9.1 10.8 12.2* 13.4*
Past stroke (%) 6.4 5.1 8.6* 10.7*
Neurologic dysfunction (%) 6.1 5.6 8.0* 13.1*
COPD (%) 19.4 20.2 24.5* 28.4*
Pulmonary hypertension (%) 2.3 1.6 2.7 3.2
Recent myocardial infarction (%) 23.2 28.0y 26.9* 26.7, P , .05
Unstable angina (%) 10.1 14.2y 10.0 8.4
NYHA class IV (%) 5.9 7.8 6.1 9.1*
Ejection fraction 30%–50% (%) 29.0 31.2 37.7* 39.6*
Ejection fraction , 30% (%) 3.3 2.4 5.2* 5.6*
Angiographic characteristics
One-vessel disease (%) 10.0 6.5y 6.7* 5.3*
Two-vessel disease (%) 32.8 30.6 29.6y 28.1*
Three-vessel disease (%) 50.4 59.1* 57.5* 60.3*
Main stem disease (%) 18.5 17.2 16.7 15.5y
Laboratory parameters
Hemoglobin (g/dL) 13.90 6 1.51 13.92 6 1.61 13.80y 6 1.58 13.19* 6 1.61
Erythrocytes (106/mL) 4.51 6 0.50 4.53 6 0.54 4.51 6 0.52 4.36* 6 0.54
Thrombocytes (103/mL) 233.4 6 67.6 237.2 6 69.6 230.7 6 65.8 236.4 6 70.4
Leukocytes (103/mL) 7.59 6 2.28 8.08* 6 3.12 7.74* 6 2.11 8.08* 6 2.37
Total cholesterol (mg/dL) 201.9 6 44.6 210.6* 6 48.9 197.7* 6 46.9 190.9* 6 47.2
Creatinine (mg/dL) 1.13 6 0.51 1.23* 6 0.61 1.16* 6 0.46 1.31* 6 0.76
Urea (mg/dL) 38.88 6 14.7 44.15* 6 23.9 42.63* 6 17.5 50.67* 6 25.4
Creatine kinase (U/L) 50.13 6 72.7 45.47* 6 65.2 51.85* 6 197 58.52y 6 105
Medications
ACE inhibitors (%) 49.1 45.2 59.7* 64.3*
Aspirin (%) 25.0 24.2 23.3 19.4*
Beta blockers (%) 71.2 66.1, P , .05 67.6* 64.8*
Diuretics (%) 18.1 20.4 28.8* 38.1*
Nitrates (%) 58.9 61.8 59.5 55.2y
Baseline characteristics for the 4 patient groups in percent (%) or as group average (with units). Tests on group equivalence are performed by the c2 test for
categorical data and for continuous variables by the Mann–Whitney test (for the latter, standard deviations [6SD] are given with the same units). COPD,
Chronic obstructive pulmonary disease;NYHA;New York Heart Association;ACE, angiotensin-converting enzyme. Significant difference toNo diabetes group:
*P , .01; yP , .05.cic and Cardiovascular Surgery c Volume 135, Number 5 1049
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Outcome No diabetes Undiagnosed diabetes Oral therapy diabetes Insulin-treated diabetes
Cardiopulmonary resuscitation (%) 1.4 4.3* 1.5 1.8
Renal failure, dalysis (%) 1.4 3.5* 1.9 8.9*
Stroke (%) 1.2 1.9 1.8 2.5*
Cerebral dysfunction (%) 4.5 6.2 6.5* 9.8*
Reintubation (%) 1.8 4.6* 2.3 4.5*
Ventilation time . 1 d (%) 4.8 9.9* 5.4 8.6*
ICU stay . 3 d (%) 26.9 28.8 31.8* 38.4*
30-d mortality (%) 0.8 2.7* 1.4 1.5y
ICU, Intensive care unit. Significant difference to No diabetes group: *P , .01; yP , 0.05.among these patient groups (no diabetes 4.8% vs undiag-
nosed diabetes 9.9 % vs oral therapy diabetes 5.4% vs insu-
lin-treated diabetes 8.6%). On average, diabetic patients with
coronary disease spend longer periods of time in the intensive
care unit (ICU) than patients without diabetes and have a sig-
nificantly higher 30-day mortality rate, with the highest mor-
tality being found in the group of patients with undiagnosed
diabetes.
Table 3 shows the two resulting regression models in
which undiagnosed diabetes, oral therapy diabetes, and insu-
lin-treated diabetes are listed. The results show that undiag-
nosed diabetes and insulin-treated diabetes are independent
risk factors for a longer period of ventilation and for more
frequent reintubation at the postoperative stage.
Discussion
Even after accounting for other risk factors such as age, body
mass index, and pre-existing chronic obstructive pulmonary
disease, the significantly longer ventilation time and the
higher frequency of reintubation among diabetic patients at
the postoperative stage is conspicuous. These results may1050 The Journal of Thoracic and Cardiovascular Surgery c Mabe explained if one considers that the respiratory function of
diabetic patients is also impaired in the course of their disease.
Pathophysiology of Lung Dysfunction in Patients
With Diabetes
The pulmonary function of patients with diabetes has been
the subject of numerous studies. Walter and associates,12
for instance, were able to show in the Framingham Heart
Study (1971–1975) that unidentified and known diabetes
mellitus was associated with reduced forced expiratory vol-
ume in 1 second (FEV1) and forced vital capacity (FVC)
values. The study by McKeever and coworkers13 and the
data of the Copenhagen City Heart Study14 confirm these
results. The latter study also showed that the most significant
impairment of pulmonary function is found among patients
with insulin-treated diabetes. These results suggest that pul-
monary function declines as the diabetic disorder progresses
over time, with some evidence to suggest that disturbances of
pulmonary function appear at quite an early stage of the dis-
ease, even before it is apparent in clinical terms. The results of
the British Women’s Heart and Health Study (1999–2001)15TABLE 3. Logistic regression analysis for the two outcomes
Diabetes status No. of events Crude OR Adjusted OR 95 % CI P
Reintubation* Undiagnosed DM 17 2.55 1.96 1.14–3.49 .02
Oral therapy DM 39 1.25 1.06 0.72–1.54 .78
Insulin-treated DM 45 2.48 1.63 1.11–2.39 .01
Ventilation time . 1 dy Undiagnosed DM 37 2.17 1.84 1.26–2.69 , .01
Oral therapy DM 91 1.11 0.94 0.73–1.21 .61
Insulin-treated DM 87 1.86 1.33 1.01–1.74 .04
Logistic regression analysis for the two outcomes ''Reintubation'' and ''Ventilation time. 1 d.'' For each outcome the crude OR (resulting from simple logistic
models where only the indicator variables ''Undiagnosed DM,'' ''Oral therapy DM,'' and ''Insulin-treated DM'' were included) and the adjusted OR with ad-
ditional covariates and the area under the receiver operating characteristic curve given in the footnote, are presented. The CIs and P values correspond
to the adjusted models, respectively. OR, Odds ratio; CI, confidence interval (for the adjusted OR); DM, diabetes mellitus. *Further covariates i of fully adjusted
model: b-blockers (0.7, 0.52–0.94), left ventricular ejection fraction (LVEF) 30% to 50% (1.42, 1.05–1.93), LVEF , 30% (2.58, 1.54–4.32*), female sex (1.38, 1.01–
1.88), leukocytes (1.05, 1.01–1.1), urea (1.02, 1.01–1.02*), unstable angina (1.62, 1.09–2.39). In parenthesis exp(betai coefficient) 2 equivalent to ORi for cate-
gorical attributes, its 95% CI, and significance indicator z for P, 0.01; area under the receiver operating characteristic curve: 0.67. yFurther covariates i of fully
adjusted model: age (1.04, 1.02–1.05z), past stroke (1.79, 1.35–2.39z), angiotensin-converting enzyme inhibitors (0.82, 0.68–1.0), diuretics (1.3, 1.05–1.62), recent
myocardial infarction (0.79, 0.63–0.99), LVEF 30% to 50% (1.43, 1.16–1.76z), LVEF , 30% (3.44, 2.45–4.83z), leukocytes (1.09, 1.05–1.12z), urea (1.01, 1.0–1.01z),
unstable angina (1.56, 1.19–2.04z). In parenthesis exp(betai coefficient) 2 equivalent to ORi for categorical attributes, its 95% CI, and significance indicator
z for P , .01; area under the receiver operating characteristic curve: 0.69.y 2008
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betes mellitus are accompanied by reduced FEV1 and FVC
values. Longitudinal studies have shown that the most pro-
nounced impairments of pulmonary function (FEV1, FVC)
were found among patients in whom diabetes had developed
during the period of observation.16 For clinically manifest
diabetes mellitus, it appears that stabilizing the blood glucose
level to near-normal values is of paramount importance.
Authors who had investigated the quality of the metabolic
management over several years in patients with type 1 diabe-
tes reported that normoglycemic patients show significantly
fewer impairments of pulmonary function.17
Evidence for a reduction in the carbon monoxide diffusion
capacity has been shown both for patients with type 1 diabe-
tes4 and for individuals with type 2 diabetes,18 with some of
these diffusion disturbances associated with signs of a dia-
betic nephropathy (albuminuria/proteinuria).4,18 The histo-
morphologic correlate of these findings has been described
in closer detail by Weynand and colleagues.5 Using autopsy
findings, the authors were able to show that the basal mem-
branes of the renal glomeruli, the alveolar epithelium, and
the capillary lung endothelium were thickened in patients
with diabetes.5
It should also be kept in mind that patients with diabetes
have specific neurologic and neuromuscular dysfunctions.
The results of various studies show, for instance, that diabetic
patients have a reduced respiratory drive under hypoxic con-
ditions.19 Studies involving individuals with type 1 diabetes
also suggest that the efficiency of the respiratory muscles is
significantly lower than in healthy test persons. With muscle
power maintained, it appears that it is the muscle perfor-
mance that is particularly impaired.20
The results of the present study also show that neurologic
damage and a state of confusion occur significantly more of-
ten among diabetic patients during the postoperative stage of
coronary bypass operations. Experience shows that these pa-
tients often take longer to be weaned from the respirator and
often have difficulty later in following the routine postoper-
ative breathing exercises under the instruction of a trained
physiotherapist.
Pathophysiology of Lung Dysfunction in the
Postoperative Course
The unique conditions of postoperative progress after coro-
nary bypass operations should be noted in this context.
More than any other organ, the lungs are adversely affected
after cardiac surgical interventions accompanied by extracor-
poreal circulation, although these dysfunctions tend to be
weak and transient. These impairments of pulmonary function
have a number of different causes. They are partly due to the
suspended or strongly reduced lung perfusion during the pe-
riod of extracorporeal circulation, which, in turn, causes lower
shear forces in the pulmonary capillaries and the activation of
neutrophil granulocytes—particularly since the neutrophilsThe Journal of Thoracappear to be especially sensitive to shear forces. The perme-
ability of the alveolar–capillary barrier increases and macro-
molecules migrate into the pulmonary interstitial space and
the alveoli and, therefore, are able to promote the development
of pulmonary edema.Amore extensive pulmonary edema can
also develop under low or normal left atrial pressure, undoubt-
edly caused by changes in the pulmonary venous and capillary
permeability, the causes of which are as yet not fully under-
stood. This phenomenon appears to be more pronounced in
older patients.21 However, more or less distinct signs of pul-
monary dysfunction are found in almost all patients.
In the course of an uncomplicated postoperative recovery,
patients usually cough up thick tracheobronchial secretions
between 24 and 72 hours after the intervention. Symptoms
such as dyspnea and tachypnea tend to subside with the onset
of this productive cough. At this point, the protein-rich liquid
that has remained in the alveoli and the interstitial space since
the use of cardiopulmonary bypass is presumably carried by
ciliary movement from the terminal bronchioli to the larger
respiratory tracts, from which it can be coughed out. The
lung volumes are usually reversibly reduced after a cardiac
surgical intervention, in particular vital capacity and the total
lung volume.22 This is presumably due to the common effects
of small, multiple atelectatic regions, the occasional collapse
of the left lower lobe, to pulmonary edema and pleural effu-
sions, and to lower inspiratory power. Blood gas analyses,
therefore, show that arterial oxygen tensions are clearly re-
duced during the postoperative stage of bypass operations.
In general, these values reach their lowest point on the second
postoperative day and do not return to the preoperative level
until 1 week or more later.23
Guazzi and colleagues24 showed that cardiac insufficiency
and diabetes mellitus result in similar disturbances of pulmo-
nary function, which suggests an additive or even a synergis-
tic effect. Under the conditions of this comorbidity, the
frequency and the extent of gas exchange disturbance were
significantly higher, with the cardiac insufficiency appearing
to unmask the diabetic micro-angiopathy of the lungs. The
outcome of our study could indicate that the above-described
pathophysiologic changes after extracorporeal circulation
(eg, pulmonary edema and alveolar protein accumulation)
could also contribute toward the unmasking of the diabetic
lung disorder.
Discussion of the Different Outcome Among the
Examined Patient Groups
Remarkably, we encountered the highest risk of pulmonary
complications in the perioperative course of coronary bypass
operations in the group of patients with newly detected diabe-
tes, keeping in mind that these patients (as shown in Table 1)
have a characteristic risk profile but, unlike the patients with
known diabetes, have not been appropriately treated.25 The
more favorable results of the patients receiving oral therapy
could conceivably be seen as evidence that the improvementic and Cardiovascular Surgery c Volume 135, Number 5 1051
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betes has resulted in a lower intensity in the diabeticmicro-an-
giopathy of the target organ lung in the course of the years. It
should also be noted that there have been significant preoper-
ative differences in the patients’ drug therapy. The lowest
number of patients treated with angiotensin-converting en-
zyme inhibitors is, for instance, found in the group of patients
with newly detected diabetes. Guazzi and associates26,27 also
demonstrated in several studies that angiotensin-converting
enzyme inhibitors in patients with cardiac insufficiency sig-
nificantly improve the conductivity of the alveolar–capillary
membrane. The effective mechanisms under discussion in-
clude the inhibition of the angiotensin-mediated collagen syn-
thesis and the activation of the prostaglandin system, which
also reduces collagen metabolism.27 These effects could con-
ceivably lead to the regression of the structural changes in the
diabetes-related thickening of the alveolar–capillary mem-
brane and therefore to an improvement in the membranous
gas exchange.
The incidence of postoperative pulmonary complications
was significantly higher among the insulin-treated patients in
our study than among the oral therapy diabetic patients. Inas-
muchas insulin therapy is usually precededby a period of treat-
ment involving oral antidiabetic agents, one may assume that
the insulin-treated patients have haddiabetes for longer periods
than the orally treated patients. Our data may therefore suggest
that, as the duration of the underlying diabetes increases, there
aremore pronouncedmorphologic changes of the lungswhich,
under the additional stress caused by the pathophysiologic
changes after cardiopulmonary bypass, could result in an
increase in the occurrence of pulmonary complications.
The issue of the risk factors for pulmonary complications
during the perioperative stage of coronary bypass operations
also entails some important aspects of health economy. Lon-
ger periods of ventilation lead to longer ICU hospitalization
periods, fewer hospital beds, and higher public health costs.
If the current demographic trends continue, the near future
will see an increasing burden on the public health system
caused by the more frequent ICU bed use by a growing num-
ber of older (and diabetic) patients. In view of these develop-
ments, it seems imperative to identify patients with a higher
risk of postoperative pulmonary complications as early as
in the preoperative stage to allow the development of preven-
tive measures and the allocation of appropriate funds.
Although pulmonary function tests and blood gas analyses
are often carried out in the course of preoperative examina-
tions, there is insufficient evidence to recommend the routine
use of these tests.28 Preoperative pulmonary function tests in
patients who underwent coronary bypass operations had no
predictive merits with regard to postoperative pulmonary
complications.29 The recommendation for the preoperative
evaluation therefore focuses on a risk stratification model
which—on the strength of the results of the present study—
should definitely include the differentiated diabetes status.1052 The Journal of Thoracic and Cardiovascular Surgery c MaHulzebos and colleagues30 were able to show that the pro-
phylactic training of inspiratory muscles before coronary
bypass operations can help to avoid pulmonary complica-
tions in the postoperative course. The outcome of the present
study suggests that it is the diabetic coronary patients, in par-
ticular, who might benefit from preoperative and intensive
respiratory training before undergoing bypass operations.
Specific physiotherapeutic efforts involving selected high-
risk patients could therefore help to avoid pulmonary compli-
cations in the perioperative course.
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